Aenitis develops innovative patented devices for the continuous handling, without contact or pressure, of suspended cells by the use of acoustic radiation forces (called acoustophoresis). Aenitis focuses on the development and sales of medical devices and lab instruments addressing bioproduction preparation issues in cell and gene therapy.

Bio Elpida is a CDMO focused on the development and cGMP manufacturing of innovative therapy based on cell culture, aseptic process and single use strategy.

GMP grade production at affordable cost of adipose tissue mesenchymal stem cells. CDMO GMP production of adherent cells.

CellProthera is a biotech company, incorporated in April 2008, and intended for the development, registration and marketing of innovative therapeutic solutions for the regeneration of organs damaged by disease or trauma from autologous blood peripheral stem cells.

The CECS is a non-profit research association, a member alongside the INSERM / UEVE 861 Unit of the I-Stem Institute, dedicated to the exploration of the therapeutic potential of stem cells in rare diseases of genetic origin. . I-Stem carries out translational research that leads to clinical trials in cell therapy and pharmacology.

Production of clinical grade human mesenchymal stromal cells in the field of tissue burns and repair. Member of the Ecell France consortium.

AP-HP MEARY Center for Cell and Gene Therapy is among the leaders in the manufacturing of ATMPs, offering cutting-edge expertise to clinicians, research teams, as well as industrial partners for the support and execution of their cell, tissue, and gene therapy clinical trials.

University hospital of Rouen Normandy advanced therapy facility NORMAcell

Company specializing in dermatocosmetics and oncology research, in particular through 3D bioprinting of complex models and in-house testing. Bio-bank accredited to the Ministry of Education and Research, with more than 50,000 samples in stock and a network of 200 partners.

EryPharm develops the production of Cultured Red Blood Cells in oder to complement the blood transfusion.

The EFS is the sole player in transfusion in France. In addition to its activities of collection, preparation, qualification and distribution of Labile Blood Products (PSL), EFS is a major player in cell and tissue therapies and in the design and production of MTI. Its CDMO activity offers clinical batch production capacities on several platforms.

Flash Therapeutics (FTX) is an integrated gene therapy company developing gene and cell-based therapies by leveraging bioproduction technologies and its proprietary lentiviral platform including regular integrative lentiviral vectors (DNA delivery) and the patented non-integrative LentiFlash® technology (RNA delivery. Both lentiviral technologies represent unique opportunities in the gene delivery field by providing complementary solutions for dedicated applications. Integrative systems lead to a stable expression of proteins or defective cell effectors and LentiFlash allows a transient expression to trigger a one-step cell mechanism as antigen or nucleases expression.

Health&Biotech France is a company developing cell terapy products to be used in for clinical applications in regenerative medicine

IPRASENSE provides cell analysers for real-time monitoring of cell cultures. Our SME, based in the Montpellier area, relies on expertise in holographic imaging acquired with CEA Leti since its creation in 2013. Our instruments focus on both the academic research and the pharmaceutical industry from the cell line development stages up to the bioproduction in GMP environment.

Keyrus Life Science is a unique Connected Clinical Research & Development Organization. We believe that it is only by making sense of data that mankind can solve the major health challenges it faces. Keyrus Life Science helps connect industry expertise, Life Data Sciences and Digital Enablement to fully leverage both Clinical Research ecosystems and Real-World Evidence/RWE in healthcare, thus enhancing the reliability, innovative capacity, agility, and, above all, speed of execution of Clinical Research activities.

With more than 40 years of experience in cryopreservation, quality and regulatory affairs, LinBox can propose solutions related to biobanks and tissues and cells grafts’ cryopreservation.

Based in the South of France, Phenocell has developed unique skills to produce human cells using the induced pluripotent stem cells (iPSC) technology. Our analytic and screening platform allows efficient identification and qualification (efficacy/toxicity) of compounds for our industrial (pharalceutics and cosmetics) partners.

Poietis is a bioprinting company specializing in the development of new biomanufacturing solutions, based on Laser-Assisted Bioprinting, for human tissues. Poietis mission is to provide clinicians and patients with tissue engineering therapies thanks to its innovative, proprietary Next-Generation Bioprinting platform (NGB).

Pioneer in neuro-engineering, Synaxys has developed "5D-brain", the first reliable human in vitro model of the central nervous system that enables functional studies and replaces animal experimentation. With 5 accessible dimensions: 3D space, time, and disease phenotype, it enhances preclinical R&D studies of biotech and pharmaceutical groups, CROs and academic laboratories in neurosciences field.

The strength of our distribution activity through the pan-European branches of our group, lies in our longstanding relationships with our suppliers. This allows us to provide first-rate service and to be the reliable source for reagents critical to our customers’ research and product development. In parallel, access to a broad selection of ethical sources, including collections of biological samples and primary cells, enables us to perform in vitro assays for understanding mechanisms of actions (MOA) and demonstrating proofs of concepts (POC) with a short turnaround time.

Thermo Fisher Scientific is the world leader in serving science, with revenues of more than $24 billion and approximately 70,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer.

TreeFrog Therapeutics is a startup company aiming at providing access to cell therapies for millions of patients. TreeFrog Therapeutics has developed C-Stem, a high-throughput cell encapsulation technology allowing the mass-production and differentiation of stem cells in industrial bioreactors.This proprietary technology platform provides an end-to-end and scalable solution that dramatically improves the quality of therapeutic cells and reduce treatment costs. Since its incorporation in November 2018 in Bordeaux, France, TreeFrog Therapeutics has experienced strong acceleration, raising over €13M ($14,65M) in 2019. In January 2020, TreeFrog Therapeutics joined the FrenchTech120, an elite programme for the fastest-growing technology companies in France. The team – currently 28 staff - moved into a brand new production facility of 13,000 sq ft in June 2020.